Nurix Therapeutics (NRIX) Cash from Operations (2019 - 2026)
Nurix Therapeutics (NRIX) posted quarterly Cash from Operations of 96573000.0 for Q2 2026, down 52.9% year-over-year from 205037051.77 in Q2 2025, and down 34.29% quarter-over-quarter from 71914000.0 in Q1 2026.
Powered by 
Analysis
Nurix Therapeutics (NRIX) Cash from Operations (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has reported Cash from Operations for 8 consecutive years, with 96573000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 52.9% year-over-year to 96573000.0; the TTM figure through May 2026 stood at 293704000.0 (down 36.49% YoY), while the FY2025 annual figure was 249465000.0, down 44.55% from the prior year.
- Cash from Operations fell to 96573000.0 in Q2 2026 per NRIX's latest filing, from 71914000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 26689000.0 in Q4 2023 and bottomed at 96573000.0 in Q2 2026.
- Historically, Cash from Operations has averaged 46206000.0 across 5 years, with a median of 44469000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 629.37% — and 2023, when it soared 170.32%.
- Nurix Therapeutics' Cash from Operations stood at 37955000.0 in 2022, then jumped by 170.32% to 26689000.0 in 2023, then plunged by 282.66% to 48751000.0 in 2024, then sank by 39.14% to 67832000.0 in 2025, then tumbled by 42.37% to 96573000.0 in 2026.
- Business Quant data shows NRIX's Cash from Operations at 96573000.0 in Q2 2026, 71914000.0 in Q1 2026, and 67832000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Nurix Therapeutics | 2.90 Bn | 2.46 Bn | - | -96.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -96.57 Mn |
| Feb 28, 2026 | -71.91 Mn |
| Nov 30, 2025 | -67.83 Mn |
| Aug 31, 2025 | -57.39 Mn |
| May 31, 2025 | -63.16 Mn |
| Feb 28, 2025 | -61.09 Mn |
| Nov 30, 2024 | -48.75 Mn |
| Aug 31, 2024 | -42.18 Mn |
| May 31, 2024 | -39.71 Mn |
| Feb 29, 2024 | -41.95 Mn |
| Nov 30, 2023 | 26.69 Mn |
| Aug 31, 2023 | -41.13 Mn |
| May 31, 2023 | -18.47 Mn |
| Feb 28, 2023 | -48.45 Mn |
| Nov 30, 2022 | -37.96 Mn |
| Aug 31, 2022 | -46.31 Mn |
| May 31, 2022 | -32.91 Mn |
| Feb 28, 2022 | -42.63 Mn |
| Nov 30, 2021 | -30.91 Mn |
| Aug 31, 2021 | -29.97 Mn |